CER's Place In Drug Development Is A Work In Progress, FDA Says
Executive Summary
FDA has a lot of work to do before it can determine how comparative effectiveness research might play into its evaluation of new drug approvals or labeling changes, Chief Scientist and Acting Deputy Commissioner for Science and Public Health Jesse Goodman told a conference sponsored by the Friends of Cancer Research June 18
You may also be interested in...
CER, Reimbursement Issues Drawing More Attention From Reg Professionals
Pharmaceutical manufacturers’ efforts to address comparative effectiveness and reimbursement issues earlier in their regulatory strategies are borne out in a study showing growing involvement by regulatory professionals in these areas.
CER, Reimbursement Issues Drawing More Attention From Reg Professionals
Pharmaceutical manufacturers’ efforts to address comparative effectiveness and reimbursement issues earlier in their regulatory strategies are borne out in a study showing growing involvement by regulatory professionals in these areas.
Drug Developers Facing "Unsettled" Period Of 5 To 10 Years As CER Environment Evolves, FDA's Woodcock Says
The growing emphasis on comparative effectiveness research as well as the many unknowns on how the process is going to evolve could create a decade of unsettlement for drug development, FDA's Janet Woodcock said